The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells.
暂无分享,去创建一个
Gustavo Helguera | T. Daniels | Tracie Delgado | G. Helguera | M. Penichet | Tracy R Daniels | Tracie Delgado | Manuel L Penichet | Tracy R. Daniels
[1] C. Lok,et al. The transferrin receptor: role in health and disease. , 1999, The international journal of biochemistry & cell biology.
[2] G. Volckaert,et al. Cloning and expression of a chimeric antibody directed against the human transferrin receptor. , 1990, Journal of Immunology.
[3] D. Newton,et al. Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice. , 1999, Journal of immunological methods.
[4] H. Hirschberg,et al. Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals , 2002, International journal of cancer.
[5] K. Muraszko,et al. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. , 1993, Cancer research.
[6] T. Szekeres,et al. Cytotoxicity of a transferrin‐adriamycin conjugate to anthracycline‐resistant cells , 1992, International journal of cancer.
[7] S. Kochanek,et al. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] I. Pastan,et al. Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[9] E. Chang,et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. , 2002, Molecular cancer therapeutics.
[10] J. Batra,et al. Generation of active immunotoxins containing recombinant restrictocin. , 1996, Biochemical and Biophysical Research Communications - BBRC.
[11] E. Chang,et al. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. , 2004, Molecular cancer therapeutics.
[12] M. Yamamoto,et al. In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex. , 1995, Journal of pharmaceutical sciences.
[13] M. Cazzola,et al. Killing of K562 cells with conjugates between human transferrin and a ribosome‐inactivating protein (SO‐6) , 1988, British journal of haematology.
[14] E. Chang,et al. Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv , 2001, Molecular medicine.
[15] L. Barbieri,et al. Ribosome–Inactivating Proteins from Plants: Present Status and Future Prospects , 1992, Bio/Technology.
[16] A. Rait,et al. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene , 2004, Gene Therapy.
[17] A. Aurengo,et al. Differential transferrin receptor density in human colorectal cancer: A potential probe for diagnosis and therapy. , 1998, International journal of oncology.
[18] E. Oldfield,et al. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors , 1997, Nature Medicine.
[19] Joseph Bertolini,et al. Transferrin: structure, function and potential therapeutic actions. , 2005, Drug discovery today.
[20] L. Recht,et al. Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro. , 1990, Cancer research.
[21] M. Pasti,et al. Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin. , 1995, British Journal of Cancer.
[22] R. Elliott,et al. Antineoplastic drugs that interfere with iron metabolism in cancer cells. , 1997, Advances in enzyme regulation.
[23] S. Morrison,et al. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[24] Yasuo Shinohara,et al. Mitochondrial delivery of mastoparan with transferrin liposomes equipped with a pH-sensitive fusogenic peptide for selective cancer therapy. , 2005, International journal of pharmaceutics.
[25] A. Goyal,et al. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. , 2000, The Biochemical journal.
[26] S. Neidle. The molecular basis for the action of some DNA-binding drugs. , 1979, Progress in medicinal chemistry.
[27] D. Ferris,et al. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon. , 1990, Cancer research.
[28] R. Stjernholm,et al. Preliminary evaluation of platinum transferrin (MPTC-63) as a potential nontoxic treatment for breast cancer. , 1988, Cancer detection and prevention.
[29] I. Trowbridge,et al. Effect of an anti-murine transferrin receptor-ricin A conjugate on bone marrow stem and progenitor cells treated in vitro. , 1984, Experimental cell research.
[30] P. Couvreur,et al. Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.
[31] S. Ramakrishnan,et al. Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: potentiation by chloroquine. , 1984, Science.
[32] V. Raso,et al. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins. , 1991, Cancer research.
[33] E. Oldfield,et al. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. , 2000, Cancer research.
[34] F Lechenault,et al. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. , 1998, Journal of pharmaceutical sciences.
[35] J. Engler,et al. Enhancement of gene delivery to cancer cells by a retargeted adenovirus. , 2005, Journal of microbiology.
[36] T. Szekeres,et al. Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells. , 1996, Biochemical pharmacology.
[37] K. Maruyama,et al. Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer , 2002, International journal of cancer.
[38] S. Sahoo,et al. Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer , 2004, International journal of cancer.
[39] C. Unger,et al. Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil. , 1998, Journal of medicinal chemistry.
[40] C. Chitambar. Gallium compounds as antineoplastic agents , 2004, Current opinion in oncology.
[41] Jörg Huwyler,et al. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. , 2004, Journal of the National Cancer Institute.
[42] I. Pastan,et al. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. , 1987, Cancer research.
[43] Michael Weaver,et al. Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas , 2003, Journal of Neuro-Oncology.
[44] S. Ramakrishnan,et al. Characterization of a translation inhibitory protein from Luffa aegyptiaca. , 1989, Biochemical and biophysical research communications.
[45] C. Richardson,et al. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma. , 1987, Cancer research.
[46] D. Richardson,et al. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. , 1997, Biochimica et biophysica acta.
[47] E. Oldfield,et al. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. , 1994, Journal of neurosurgery.
[48] L. Polito,et al. Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation , 2002, European journal of clinical investigation.
[49] Tetsuro Tanaka,et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). , 2004, International journal of pharmaceutics.
[50] B. Chabner,et al. Cancer Chemotherapy: Principles and Practice , 1990 .
[51] V. Raso,et al. A highly cytotoxic human transferrin-ricin A chain conjugate used to select receptor-modified cells. , 1984, The Journal of biological chemistry.
[52] R. Micetich,et al. Transferrin directed delivery of adriamycin to human cells. , 1998, Anticancer research.
[53] I. Trowbridge,et al. Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells , 1981, Nature.
[54] R. Youle,et al. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. , 1987, Science.
[55] R. Elliott,et al. Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. , 2000, Anticancer research.
[56] L. Šabová,et al. Anti-apoptotic proteins-targets for chemosensitization of tumor cells and cancer treatment. , 2005, Neoplasma.
[57] H. Koeffler,et al. Molecular Cloning of Transferrin Receptor 2 , 1999, The Journal of Biological Chemistry.
[58] D. Newton,et al. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. , 1996, Biochemistry.
[59] W. Faulk,et al. Evidence in Support of the Plasma Membrane as the Target for Transferrin‐Adriamycin Conjugates in K562 Cells , 1991, American journal of reproductive immunology.
[60] A. Frankel. Increased sophistication of immunotoxins. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[61] A. Bérczi,et al. Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells. , 1993, Archives of biochemistry and biophysics.
[62] S. Rybak,et al. Humanization of immunotoxins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[63] P. Cheng,et al. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. , 2002, Human gene therapy.
[64] K. Ohkawa,et al. Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro. , 1993, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[65] M. Cazzola,et al. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors. , 1991, Cancer research.
[66] J. Fernandes,et al. Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[67] I. Pastan,et al. Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. , 2000, International journal of oncology.
[68] M. Pagé,et al. Cytotoxicity of transferrin-daunorubicin conjugates on small cell carcinoma of the lung (SCCL) cell line NCI-H69. , 1991, Anticancer research.
[69] G. Marcucci,et al. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[70] R. Draper,et al. Characterization of a transferrin-diphtheria toxin conjugate. , 1985, The Journal of biological chemistry.
[71] S. Leppla,et al. Inhibition of diphtheria toxin degradation and cytotoxic action by chloroquine. , 1980, The Journal of biological chemistry.
[72] K. Sandvig,et al. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. , 1996, Physiological reviews.
[73] I. Pastan,et al. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv) , 1991, Molecular and cellular biology.
[74] J. Jackson,et al. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors. , 1987, Journal of the National Cancer Institute.
[75] Qi Zhou,et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. , 2005, Human gene therapy.
[76] H. Yanagie,et al. Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.
[77] Gengfeng Fu,et al. Potent inhibition of angiogenesis and liver tumor growth by administration of an aerosol containing a transferrin-liposome-endostatin complex. , 2003, World journal of gastroenterology.
[78] I. Pastan,et al. Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines. , 1988, Cancer research.
[79] Ernst Wagner,et al. Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. , 2003, Bioconjugate chemistry.
[80] E. Oldfield,et al. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. , 1989, Journal of neurosurgery.
[81] T. Tagawa,et al. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome , 2005, Molecular Cancer Therapeutics.
[82] D. Newton,et al. Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv. , 1994, The Journal of biological chemistry.
[83] M. Fritzer,et al. Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. , 1993, European journal of biochemistry.
[84] J. Batra,et al. Construction, expression and characterization of chimaeric toxins containing the ribonucleolytic toxin restrictocin: intracellular mechanism of action. , 1997, The Biochemical journal.
[85] E. Chang,et al. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. , 2002, Human gene therapy.
[86] R. Youle,et al. The role of the diphtheria toxin receptor in cytosol translocation. , 1988, The Journal of biological chemistry.
[87] S. Nayak,et al. Overproduction of fungal ribotoxin alpha-sarcin in Escherichia coli: generation of an active immunotoxin. , 1997, Gene.
[88] I. Pastan,et al. Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. , 1985, Cancer research.
[89] Jianjun Cheng,et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles , 2004, Cancer biology & therapy.
[90] Debbie Trinder,et al. Transferrin receptor 2: a new molecule in iron metabolism. , 2003, The international journal of biochemistry & cell biology.
[91] T. Daniels,et al. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. , 2006, Clinical immunology.
[92] H. Yanagie,et al. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[93] T. Suhara,et al. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. , 2004, International journal of pharmaceutics.
[94] C. Ciudad,et al. Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[95] A. Rivera,et al. Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosis. , 2004, Virology.
[96] Mary Edson,et al. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity , 2005, Cancer Immunology, Immunotherapy.
[97] N. Smith,et al. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. , 2003, The Journal of urology.
[98] M. Hashida,et al. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. , 1995, Critical reviews in oncology/hematology.
[99] F. L. Crane,et al. Inhibition of transplasma membrane electron transport by transferrin-adriamycin conjugates. , 1992, Biochimica et biophysica acta.
[100] S. Rybak,et al. Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. , 1991, The Journal of biological chemistry.
[101] Hiroshi Kawabata,et al. Transferrin Receptor 2-α Supports Cell Growth Both in Iron-chelated Cultured Cells and in Vivo * , 2000, The Journal of Biological Chemistry.
[102] W. Faulk,et al. Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA. , 1992, The Journal of biological chemistry.
[103] S. Leppla,et al. Immunotoxin therapy of hematologic malignancies. , 2003, Seminars in oncology.
[104] M. Brunori,et al. A chimeric saporin‐transferrin conjugate compared to ricin toxin: role of the carrier in intracellular transport and toxicity , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[105] H. Moon,et al. Intratumoral Injection of 188Re labeled Cationic Polyethylenimine Conjugates: A Preliminary Report , 2004, Journal of Korean medical science.